• 1
    Sugiyama T,Kamura T,Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000; 88: 25842589.
  • 2
    Hess V,A'Hern R,Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. JClin Oncol. 2004; 22: 10401044.
  • 3
    Brown E,Stewart M,Rye T, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer. 2004; 100: 21482153.
  • 4
    Long ME,Taylor HCJr. Endometrioid carcinoma of the ovary. Am J Obstet Gynecol. 1964; 90: 936950.
  • 5
    Brescia RJ,Dubin N,Demopoulos RI. Endometrioid and clear cell carcinoma of the ovary. Factors affecting survival. Int J Gynecol Pathol. 1989; 8: 132138.
  • 6
    Grosso G,Raspagliesi F,Baiocchi G,Di Re E,Colavita M,Cobellis L. Endometrioid carcinoma of the ovary: a retrospective analysis of 106 cases. Tumori. 1998; 84: 552557.
  • 7
    Kline RC,Wharton JT,Atkinson EN,Burke TW,Gershenson DM,Edwards CL. Endometrioid carcinoma of the ovary: retrospective review of 145 cases. Gynecol Oncol. 1990; 39: 337346.
  • 8
    Soliman PT,Slomovitz BM,Broaddus RR, et al. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol. 2004; 94: 456462.
  • 9
    Tidy J,Mason WP. Endometrioid carcinoma of the ovary: a retrospective study. Br J Obstet Gynaecol. 1988; 95: 11651169.
  • 10
    Zaino R,Whitney C,Brady MF,DeGeest K,Burger RA,Buller RE. Simultaneously detected endometrial and ovarian carcinomas—a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol. 2001; 83: 355362.
  • 11
    Aure JC,Hoeg K,Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol. 1971; 37: 19.
  • 12
    Czernobilsky B,Silverman BB,Mikuta JJ. Endometrioid carcinoma of the ovary. A clinicopathologic study of 75 cases. Cancer. 1970; 26: 11411152.
  • 13
    Dembo AJ,Bush RS. Current concepts in cancer: ovary—treatment of stages III and IV. Choice of postoperative therapy based on prognostic factors. Int J Radiat Oncol Biol Phys. 1982; 8: 893897.
  • 14
    Einhorn N,Nilsson B,Sjovall K. Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population. Cancer. 1985; 55: 20192025.
  • 15
    Malkasian GDJr,Melton LJ3rd,O'Brien PC,Greene MH. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol. 1984; 149: 274284.
  • 16
    Sorbe B,Frankendal B,Veress B. Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol. 1982; 59: 576582.
  • 17
    Tornos C,Silva EG,Khorana SM,Burke TW. High-stage endometrioid carcinoma of the ovary. Prognostic significance of pure versus mixed histologic types. Am J Surg Pathol. 1994; 18: 687693.
  • 18
    Shevchuk MM,Winkler-Monsanto B,Fenoglio CM,Richart RM. Clear cell carcinoma of the ovary: a clinicopathologic study with review of the literature. Cancer. 1981; 47: 1344135.
  • 19
    Rustin GJ,Nelstrop AE,Tuxen MK,Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol. 1996; 7: 361364.
  • 20
    Rustin GJ,Nelstrop AE,Bentzen SM,Bond SJ,McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol. 2000; 18: 17331739.
  • 21
    Bjorkholm E,Pettersson F,Einhorn N,Krebs I,Nilsson B,Tjernberg B. Long-term follow-up and prognostic factors in ovarian carcinoma. The radiumhemmet series 1958 to 1973. Acta Radiol Oncol. 1982; 21: 413419.
  • 22
    Zwart J,Geisler JP,Geisler HE. Five-year survival in patients with endometrioid carcinoma of the ovary versus those with serous carcinoma. Eur J Gynaecol Oncol. 1998; 19: 225228.
  • 23
    Garzetti GG,Ciavattini A,Goteri G, et al. Endometrioid carcinoma of the ovary. Retrospective study. Eur J Gynaecol Oncol. 1993; 14: 5155.
  • 24
    Voest EE,van Houwelingen JC,Neijt JP. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log [relative risk]) as main objectives. Eur J Cancer Clin Oncol. 1989; 25: 711720. Comment in:Eur J Cancer Clin Oncol.1989;25:1901.
  • 25
    Obata K,Morland SJ,Watson RH, et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 1998; 58: 20952097.
  • 26
    Sato N,Tsunoda H,Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000; 60: 70527056.
  • 27
    Saito M,Okamoto A,Kohno T, et al. Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer. 2000; 85: 160165.
  • 28
    Campbell IG,Russell SE,Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004; 64: 76787681.
  • 29
    Catasus L,Bussaglia E,Rodrguez I, et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol. 2004; 35: 13601368.
  • 30
    Lassus H,Leminen A,Lundin J,Lehtovirta P,Butzow R. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol. 2003; 91: 504512.
  • 31
    Reles A,Wen WH,Schmider A, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clinical Cancer Res. 2001; 7: 29842997.
  • 32
    Wu R,Hendrix-Lucas N,Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell. 2007; 11: 321333.